Fortfahren mit
C3160
Complement C5 from human serum
≥90% (SDS-PAGE), >100,000 C5H50 units/mg protein
Synonym(e):
C5 human, Complement C5
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 0.1 mg | Warenkorb auf Verfügbarkeit prüfen | € 343,00 |
Über diesen Artikel
Form:
solution
Assay:
≥90% (SDS-PAGE)
Biological source:
human serum
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenApplication
Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.
Biochem/physiol Actions
Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.
Analysis Note
Functionally active by a sensitive hemolytic assay.
Other Notes
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| assay ≥90% (SDS-PAGE) | assay ≥85% (SDS-PAGE) | assay ≥95% (SDS-PAGE) | assay ≥90% (SDS-PAGE) |
| technique(s) activity assay: suitable | technique(s) immunoelectrophoresis: suitable | technique(s) - | technique(s) activity assay: suitable |
| biological source human serum | biological source human | biological source - | biological source human plasma |
| concentration 1 mg/mL in PBS, pH 7.2 | concentration 1 mg/mL in PBS, pH 7.2 | concentration - | concentration 1 mg/mL in PBS, pH 7.2 |
| form solution | form solution | form liquid | form liquid |
| Gene Information human ... C5(727) | Gene Information human ... C8A(731) | Gene Information - | Gene Information human ... CFH(3075) |
Lagerklasse
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
The role of complement inhibition in PNH.
Hillmen P.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2008(1), 116-123 (2008)
Peter Hillmen et al.
The New England journal of medicine, 350(6), 552-559 (2004-02-06)
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement
A M Risitano et al.
Mini reviews in medicinal chemistry, 11(6), 528-535 (2011-05-13)
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evident chronic hemolysis due to the absence of the complement regulators CD55 and CD59 on PNH
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C3160-.1MG | 04061833420164 |